Is ilumya a biologic?

Yes, Ilumya is classified as a biologic drug [1].

What kind of biologic is Ilumya?

Ilumya is a monoclonal antibody [1]. Specifically, it is a human IgG1 monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23) [1].

How does Ilumya work?

By inhibiting IL-23, Ilumya blocks the interaction of IL-23 with its receptor and reduces the release of pro-inflammatory cytokines, such as IL-17 and IL-22 [1]. This mechanism of action is key to its therapeutic effect in certain inflammatory conditions.

What is Ilumya used to treat?

Ilumya is approved for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy [1].

Who makes Ilumya?

Ilumya is developed and marketed by AbbVie [1].

When might Ilumya's patent protection end?

Patent expiry dates can be complex due to various factors including different patent types and potential litigation. For detailed information on Ilumya's patent landscape and projected expiry dates, resources like DrugPatentWatch.com can provide specific insights [2].